Batu Biologics Strategy For FDA Approval Of Lung Cancer Immunotherapy Featured In San Diego Business Journal
7/28/2014 9:38:12 AM
SAN DIEGO--(BUSINESS WIRE)--Batu Biologics announced today that it’s President and CEO, Samuel C. Wagner, was featured in the weekly business publication, the San Diego Business Journal. The article, which was published in the July 21st edition, discussed the company’s strategy in developing its immunotherapeutic lung cancer vaccine, ValloVax, for which FDA Investigational New Drug (IND) submission is planned in Q1 of 2015.
Help employers find you! Check out all the jobs and post your resume.
comments powered by